Tamara Braut | Cancer Cell Biology | Innovative Research Award

Posted on by Cell Biologist

Prof. Dr. Tamara Braut | Cancer Cell Biology | Innovative Research Award

Prof. Dr. Tamara Braut | Faculty of Medicine, University of Rijeka/ENT Clinic, Clinical hospital centre Rijeka | Croatia

Professor Tamara Braut, MD, is a renowned Croatian otorhinolaryngologist and Full Professor at the Faculty of Medicine, University of Rijeka. She serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery. Her clinical expertise and academic leadership have significantly contributed to advancements in the diagnosis and treatment of head and neck cancers, particularly laryngeal carcinoma. With over two decades of experience, Dr. Braut is widely recognized for her work in molecular oncology, HPV-associated head and neck tumors, and translational medicine. A frequent collaborator on interdisciplinary and international projects, she is committed to personalized medicine and innovative approaches in clinical research. Her impressive portfolio of peer-reviewed publications, including case studies, multicenter analyses, and biomarker-based diagnostics, highlights her dedication to evidence-based practice and academic excellence. Professor Braut’s academic leadership and clinical insight place her among the top contributors in her specialty within Croatia and internationally.

Publication Profile:

Google Scholar

Strengths For Award:

  • Pioneering work in head and neck oncology and molecular diagnostics

  • Significant publication record in high-impact journals

  • Collaborative multicenter research and precision medicine orientation

  • Demonstrated leadership in academic and clinical settings

  • Integration of clinical insights with research innovation

Areas for Improvement:

  • Broaden research beyond oncology to explore ENT-related AI/technology

  • Increase international collaborations and visibility at global conferences

  • Expand into clinical trials for therapeutics in HPV+ cancers

🎓 Education: 

Prof. Tamara Braut received her Doctor of Medicine (MD) degree from the University of Rijeka, Croatia, where she also completed her specialization in Otorhinolaryngology. Her academic path was distinguished by an early interest in oncology, molecular pathology, and surgical innovation. She pursued postgraduate training and research with a focus on laryngeal and head and neck cancers. Throughout her education, she was actively involved in academic research, participating in numerous national and international conferences, which sharpened her analytical and investigative skills. She later obtained her PhD with a focus on molecular markers in squamous cell carcinoma. Over the years, she has pursued continuous professional development in precision medicine, oncology biomarkers, and evidence-based surgical practices. Her academic and clinical training has made her a highly competent physician-scientist, well-versed in both patient care and experimental research.

🧑‍🔬 Experience:

Prof. Tamara Braut has over two decades of experience in clinical and academic medicine. She currently serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery at the Faculty of Medicine, University of Rijeka. Her career spans clinical work, academic leadership, surgical practice, and scientific research. She has treated complex cases involving laryngeal and head-neck cancers and has led multidisciplinary teams in oncology care. As an educator, she has supervised medical students, residents, and PhD candidates, many of whom now hold academic and clinical positions. Dr. Braut is a prolific researcher, contributing to over 40 peer-reviewed articles, case studies, and reviews. Her leadership in multicenter studies and her role as a principal investigator in several clinical research projects highlight her competence in collaborative and innovative medical research.

🔬 Research Focus:

Prof. Braut’s research focus lies at the intersection of head and neck oncology, molecular diagnostics, and personalized medicine. She has a keen interest in biomarker discovery, especially in HPV-positive head and neck squamous cell carcinomas, and the role of EGFR signaling pathways in cancer progression. Her work includes translational research linking clinical findings with molecular data to improve prognosis, diagnosis, and treatment strategies. She has also explored the impact of hormonal therapies, gene expression markers like Ki-67 and IMP3, and novel imaging and diagnostic tools. In recent years, she has expanded her interest to gastroesophageal reflux disease and its implications in ENT disorders. Her contributions reflect a consistent commitment to advancing precision medicine, long-term patient follow-up, and multimodal treatment outcomes. She continues to integrate research into clinical practice, thereby fostering innovation and improved patient care in the otorhinolaryngology field.

📚 Publications List Top Notes:

  1. 🧬 Laryngeal SCC shows stronger Nectin-4 vs Nectin-2 expression – CIMB (2025)

  2. 🥗 GERD Management: From PPIs to Diet & Lifestyle – Gastrointest. Disord. (2025)

  3. 🔍 Advances in HPV-Positive Head & Neck Cancer Diagnostics – Biomolecules (2024)

  4. 🧪 Biomarkers in HPV+ Head and Neck SCC: Precision Medicine – Diagnostics (2024)

  5. 💉 Testosterone Therapy in Advanced Head & Neck SCC – Crit. Rev. Oncol. Hematol. (2023)

  6. 🏥 Long-Term Care in Laryngeal Cancer: Multicenter Analysis – J Pers. Med (2023)

  7. 📊 5-Year Clinical Course in Laryngeal Tumors – Acta Clin. Croatica (2022)

  8. 🧫 Renal Cell Carcinoma Metastasis to Larynx: Rare Case – Medicina Flum (2021)

  9. 🧠 Posttraumatic Vernet Syndrome without Fracture: Case Study – Medicine (2021)

  10. ⚛️ Nuclear EGFR Expression = Poor Survival in Laryngeal Ca – AIMM (2021)

Conclusion:

Prof. Tamara Braut is highly deserving of the Innovative Research Award. Her work showcases originality, clinical relevance, and scientific depth. With a robust academic and clinical foundation, she continues to push the boundaries in ENT oncology and diagnostics.

 

Weikuan Gu | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Weikuan Gu | Cancer Cell Biology | Best Researcher Award

Prof. Weikuan Gu , UTHSC , United States

Weikuan Gu is a Professor at the University of Tennessee Health Science Center, specializing in biomedical research with a focus on disease modeling, genetic factors influencing health, and drug efficacy. After earning his MS and Ph.D. from Cornell University, he worked on eye diseases, osteoporosis, and genetics before joining UTHSC in 2002. His contributions in AI applications for biomedical research are noteworthy. He has developed the Principal Law of Lifespan (PLOSP) theory and has been recognized for his leadership in various international collaborative projects. With a significant role in numerous NIH-funded studies, his research continues to push boundaries in understanding disease mechanisms and therapeutics.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Extensive Research Experience: Professor Weikuan Gu has over two decades of experience in biomedical research, demonstrating expertise across a wide array of disease models, drug efficacy, and genetic factors influencing health. His work spans a variety of high-impact fields such as ophthalmology, osteoporosis, arthritis, and genomics, showcasing a strong commitment to advancing understanding in multiple medical domains.

  2. Innovative Research Leadership: Professor Gu has been instrumental in leading and contributing to groundbreaking research, including his development of the Principal Law of Lifespan (PLOSP). His ability to innovate, especially in applying AI to biomedical research, positions him at the forefront of cutting-edge science and technology.

  3. Funded Projects & International Collaborations: He has secured substantial funding for his projects, totaling millions of dollars, and has led many high-profile international collaborations. This speaks to the global relevance and potential impact of his work, as well as his ability to manage large-scale research initiatives.

  4. Research Output and Citations: With 175 published scientific papers and multiple accepted articles in prestigious journals such as Cancer Letters and Ecotoxicology and Environmental Safety, his research continues to have a significant impact on the scientific community. His most recent work on AI applications and its implications for public health and disease diagnosis are particularly notable.

  5. Contribution to Education and Training: Professor Gu has played a key role in training future researchers, as evident from his leadership in the Gene Discovery Microarray Core at UTHSC and his involvement in several research education collaborations internationally. His contributions to scientific training are essential for developing the next generation of researchers.

Areas for Improvement:

  1. Broader Public Outreach: While Professor Gu’s research has made significant contributions to the scientific community, there is room to enhance the visibility of his work among broader audiences, including policy makers, healthcare professionals, and the general public. Public engagement with his AI-focused research could improve the real-world application of his findings, especially in public health.

  2. Interdisciplinary Collaboration: Although his collaborations are already diverse, fostering even more interdisciplinary collaborations with experts from areas like data science, engineering, and social sciences could expand the scope of his research, especially in areas like AI and healthcare.

Education:

Dr. Gu completed his MS and Ph.D. from Cornell University, where he specialized in molecular genetics. His academic journey focused on genetic disorders, particularly in disease modeling and understanding complex genetic mechanisms. His research provided foundational insights into eye diseases and osteoporosis, leading to his early work at Loma Linda University and later at the University of Tennessee Health Science Center. His vast academic knowledge enables him to merge genetic research with cutting-edge technologies, including AI applications in biomedical research, paving the way for transformative healthcare solutions.

Experience:

Dr. Weikuan Gu has a rich career that spans over two decades in biomedical research. His early work at Loma Linda University involved osteoporosis and genetic studies in human and mouse models. Since joining the University of Tennessee Health Science Center in 2002, his research expanded to disease modeling, drug efficacy, and the role of genetics in health. He has been a principal investigator and co-investigator in numerous NIH-funded projects, specializing in genetic factors influencing diseases like osteoarthritis, fibrotic diseases, and stroke. Additionally, he is involved in AI-based research, advancing the integration of AI in biomedical research methodologies.

Research Focus:

Dr. Weikuan Gu’s research is centered on understanding disease mechanisms and therapeutic strategies, with a focus on genetic and molecular factors. His work spans glaucoma therapy, fibrotic diseases, and AI in biomedical research. He is the lead on various NIH-funded projects, investigating genetic regulation in conditions like osteoarthritis and stroke. One of his innovative contributions is the Principal Law of Lifespan (PLOSP), a theory aimed at understanding the aging process. His multidisciplinary approach, combining traditional genetic research with modern technologies such as AI, positions him at the forefront of cutting-edge biomedical research.

Publications Top Notes:

  1. “Generating Research Hypotheses to Overcome Key Challenges in the Early Diagnosis of Colorectal Cancer – Future Application of AI” 🧬
  2. “Alarm: Retracted Articles on Cancer Imaging Are Not Only Continuously Cited by Publications but Also Used by ChatGPT to Answer Questions” 💻
  3. “Evaluation of the Potential Value of Artificial Intelligence (AI) in Public Health Using Fluoride Intake as the Example” 🤖

Conclusion:

Professor Weikuan Gu is an exceptionally qualified candidate for the Best Researcher Award. His extensive experience, leadership in innovative research, impressive body of published work, and commitment to advancing both scientific discovery and education make him a standout candidate. While there are opportunities for further enhancing public outreach and expanding interdisciplinary collaborations, his ongoing contributions to AI in biomedicine and genetic research firmly establish him as a leader in his field.

Vaibhav Rajoriya | Cancer Cell Biology | Cell Biology Research Award

Posted on by Cell Biologist

Mr. Vaibhav Rajoriya | Cancer Cell Biology | Cell Biology Research Award

Mr. Vaibhav Rajoriya , Oriental University, Indore , India

Vaibhav Rajoriya is a dedicated and accomplished researcher and pharmacist based in Sagar, Madhya Pradesh, India. With a strong academic background, he has earned his B.Pharm and M.Pharm from renowned institutions. He is a registered pharmacist with the MP State Pharmacy Council and holds memberships in various professional organizations, including the Association of Pharmacy Professionals. As a passionate researcher, Vaibhav has contributed to numerous studies, particularly focusing on nanomedicine, drug delivery systems, and cancer therapies. He has received prestigious fellowships such as ICMR-SRF and CSIR-SRF, contributing significantly to the field of pharmaceutical sciences. Currently pursuing a Ph.D., Vaibhav’s work continues to push boundaries in pharmaceutical research and development. His drive for excellence is further reflected in his active participation in various national and international conferences and research collaborations.

Publication Profile:

Orcid

Strengths for the Award:

  1. Diverse and Strong Research Background:
    • Vaibhav Rajoriya has a robust academic and research profile, with an established history of contributions to pharmaceutical sciences, particularly in the areas of drug delivery, nanotechnology, and cancer therapies.
    • He has authored multiple publications in high-impact journals, such as International Journal of Pharmaceutics and Current Nanomedicine, which demonstrate his expertise in nanomedicine, drug delivery systems, and the pharmaceutical applications of lipid nanoparticles and nanogels.
    • His focus on cutting-edge research areas, such as lung cancer targeting with folate-conjugated nanoparticles and novel drug delivery systems using solid lipid nanoparticles, shows a clear alignment with important biological research themes, including targeted therapy and cellular uptake.
  2. Research Achievements and Awards:
    • He has received prestigious recognitions, such as the MPCST Young Scientist Award and Best Poster Awards from institutions like AIIMS, Rishikesh, and IIT-BHU. These accolades reflect the high quality and relevance of his work in the biomedical field.
    • His successful completion of ICMR-SRF and CSIR-SRF fellowships exemplifies his ability to lead significant research projects. Moreover, he has actively contributed to a variety of projects in pharmaceutical science, indicating a deep understanding of the complexities of drug formulations, targeting mechanisms, and therapeutic applications.
  3. Ph.D. Candidacy and Future Potential:
    • Vaibhav Rajoriya is currently pursuing a Ph.D. at Oriental University, Indore, demonstrating his commitment to further advancing his research capabilities and contributing to cutting-edge research in cell biology and drug development.
    • His experience and involvement in multi-disciplinary projects, along with his fellowship positions, position him to be a strong contender for advanced research awards, including in the field of cell biology.
  4. Collaborative and Multi-dimensional Approach:
    • His involvement in collaborative research is evident through co-authorship in studies that blend different scientific approaches (nanotechnology, pharmacology, and medicinal chemistry). Such collaborations show his adaptability and the potential for cross-pollination of ideas between different scientific domains, an important characteristic in cell biology research.

Areas for Improvement:

  1. Focus on Cell Biology-Specific Research:
    • While Vaibhav’s work in nanomedicine and drug delivery systems has implications for cell biology, the research could benefit from a more explicit focus on cell biology topics such as cell signaling, cell-matrix interactions, or cell morphology, particularly at the molecular level.
    • His research could further explore in vivo and ex vivo models to study the cellular response in the context of drug delivery, providing a direct link to cellular behavior and biological mechanisms.
  2. Publication Expansion in Cell Biology Journals:
    • While his work is widely published in pharmaceutically inclined journals, increasing the number of publications directly in cell biology and molecular biology journals would provide a stronger case for this specific award. It could enhance his visibility and establish his position as a leading researcher in this field.
  3. Broader Approach to Targeted Drug Delivery in Cell Biology:
    • The research could be expanded by investigating multi-targeted delivery systems that engage specific cell types or signaling pathways, thereby providing deeper insights into cellular responses to treatment, as well as optimizing efficacy in various disease models, particularly cancer and genetic disorders.

Education:

Vaibhav Rajoriya’s educational journey is marked by a focus on pharmaceutical sciences and research. He completed his Standard X and XII from Jain Higher Secondary School, Sagar, achieving 69% and 68%, respectively. Vaibhav pursued his B.Pharm from Sagar Institute of Pharmaceutical Sciences, securing 70.4% and completed his M.Pharm at Adina Institute of Pharmaceutical Sciences with an impressive 79.9%. In addition to his pharmaceutical qualifications, Vaibhav obtained a PGDCA (Post Graduate Diploma in Computer Applications) from Agrabhan Institute of Excellence. His pursuit of knowledge led him to enroll in a Ph.D. program at Oriental University, Indore, in 2022, to further his expertise in pharmaceutical research. Throughout his academic career, he has demonstrated a strong foundation in various fields, including drug delivery systems and nanotechnology, which continues to shape his innovative research.

Experience”

Vaibhav Rajoriya has extensive experience in the field of pharmaceutical sciences, with a career that spans various research positions and projects. He was a Junior Research Fellow (JRF) in the DST-SERB-sponsored project from May 2016 to June 2018, followed by a Project Fellow position in the MPCST-sponsored research project from 2014 to 2016. These roles allowed him to gain hands-on experience in scientific research, contributing to the advancement of drug delivery systems and nanomedicine. Vaibhav has been awarded prestigious fellowships, including the ICMR-SRF (2018–2021), which further honed his skills in biomedical research. He has worked on numerous research topics, particularly focused on targeted drug delivery for cancer and other diseases, which resulted in multiple publications in high-impact journals. Vaibhav’s expertise spans the development of nanoparticle-based drug delivery systems, nano-lipid carriers, and the formulation of pharmaceutical compounds with specific targeting properties.

Awards and Honors:

Vaibhav Rajoriya’s exceptional contributions to pharmaceutical sciences have earned him several prestigious awards and honors. Notably, he was the recipient of the MPCST Young Scientist Award in 2018, recognizing his contributions to innovative research in nanomedicine. He has also earned accolades for his research presentations, including the Best Poster Award at AIIMS, Rishikesh, in 2018, for his work on folate-conjugated solid lipid nanoparticles for cancer treatment. In addition, Vaibhav won the Outstanding Poster Presentation Award in the Life Sciences category at the 1st National Biomedical Research Competition in 2018. His work at the 3rd SPIRIT 2019 conference earned him the 3rd position in the poster presentation, further highlighting his research prowess. These accolades reflect Vaibhav’s deep commitment to advancing pharmaceutical research, particularly in targeted drug delivery systems and cancer therapies, as well as his ability to effectively communicate his findings on national and international platforms.

Research Focus:

Vaibhav Rajoriya’s research focus lies primarily in the development of novel drug delivery systems, particularly for cancer treatment and other chronic diseases. His work explores the use of nanomedicine, including the formulation of solid lipid nanoparticles, nano-lipid carriers, and targeted drug delivery systems. Vaibhav’s research aims to enhance the bioavailability and therapeutic efficacy of drugs, particularly in targeted therapies for lung carcinoma and other cancers. He is particularly interested in the design and optimization of nanoparticles conjugated with targeting moieties such as folate and mannosylation to improve cellular uptake and reduce side effects. Through his research, Vaibhav has contributed to the advancement of nanocarriers for targeted drug delivery, studying their physicochemical properties, drug release profiles, cytotoxicity, and in vivo behavior. His focus is on using cutting-edge nanotechnology to create more effective and precise drug therapies for patients, particularly in oncology and infectious diseases.

Publications Top Notes:

  1. “Lactosaminated-Nsuccinyl Chitosan Nanoparticle for Hepatocyte-Targeted Delivery of Acyclovir” 🧬
  2. “Glycyrrhizin Conjugated Chitosan Nanoparticles for Hepatocyte-Targeted Delivery of Lamivudine” 💊
  3. “Mannosylated Solid Lipid Nanoparticles for Lung Targeted Delivery of Paclitaxel” 🌱
  4. “Folate-Conjugated Albumin Nanoparticles for Rheumatoid Arthritis-Targeted Delivery of Etoricoxib” 🦴
  5. “Development and Validation of RP-HPLC Method for Theophylline and Motelukast Estimation” 🔬
  6. “Evaluation of Ethanolic Extract of Zizyphus Xylopyrus on Wound Healing Activity” 🩹
  7. “Formulation Development and Evaluation of Fast Dissolving Tablet of Ramipril” 💊
  8. “UV-Spectrophotometric and Stability-Indicating RP-HPLC Method for Amlodipine and Indapamide” 📊
  9. “Folate-Conjugated Nano-Lipid Construct of Paclitaxel for Site-Specific Lung Squamous Carcinoma Targeting” 🫁
  10. “Nanostructured Lipid Carriers for Lung Cancer Targeting” 💥

Conclusion:

Vaibhav Rajoriya is a highly capable and promising researcher with strong achievements in pharmaceutical sciences, nanomedicine, and drug delivery systems. His research in the area of targeted drug delivery to specific cell types (e.g., cancer cells) already touches on key aspects of cell biology. His extensive background in various fellowships and awards underscores his dedication and success in research.